Stevanato Group (NYSE:STVN) Shares Gap Up – Still a Buy?

Stevanato Group S.p.A. (NYSE:STVN) shares gapped up prior to trading on Thursday . The stock had previously closed at €17.33, but opened at €18.25. Stevanato Group shares last traded at €18.21, with a volume of 24,427 shares changing hands.

Wall Street Analysts Forecast Growth

Several research firms recently commented on STVN. Citigroup lowered their target price on Stevanato Group from $32.00 to $26.00 and set a “buy” rating on the stock in a research report on Thursday, March 5th. KeyCorp lowered their target price on Stevanato Group from $37.00 to $32.00 and set an “overweight” rating on the stock in a research report on Thursday, March 5th. Wall Street Zen cut Stevanato Group from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Jefferies Financial Group set a $17.50 target price on Stevanato Group in a research report on Tuesday, February 10th. Finally, Morgan Stanley lowered their target price on Stevanato Group from $24.00 to $19.00 and set an “equal weight” rating on the stock in a research report on Friday, March 6th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold”.

Stevanato Group Trading Up 1.5%

The business has a 50 day simple moving average of €15.68 and a 200-day simple moving average of €18.18. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.11 and a current ratio of 1.63. The stock has a market capitalization of $5.49 billion, a P/E ratio of 30.72, a price-to-earnings-growth ratio of 1.64 and a beta of 0.75.

Stevanato Group (NYSE:STVN) last issued its quarterly earnings results on Friday, May 8th. The company reported €0.11 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of €0.12 by (€0.01). The firm had revenue of €273.57 million for the quarter. Stevanato Group had a net margin of 11.76% and a return on equity of 10.27%. The business’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.10 earnings per share. On average, analysts predict that Stevanato Group S.p.A. will post 0.68 EPS for the current year.

Hedge Funds Weigh In On Stevanato Group

A number of institutional investors and hedge funds have recently added to or reduced their stakes in STVN. GW&K Investment Management LLC boosted its stake in shares of Stevanato Group by 76.2% during the 4th quarter. GW&K Investment Management LLC now owns 2,440 shares of the company’s stock worth $49,000 after acquiring an additional 1,055 shares in the last quarter. Fifth Third Bancorp boosted its stake in shares of Stevanato Group by 22.6% during the 1st quarter. Fifth Third Bancorp now owns 4,196 shares of the company’s stock worth $58,000 after acquiring an additional 773 shares in the last quarter. State of Wyoming boosted its stake in shares of Stevanato Group by 39,216.7% during the 2nd quarter. State of Wyoming now owns 2,359 shares of the company’s stock worth $58,000 after acquiring an additional 2,353 shares in the last quarter. Quantbot Technologies LP bought a new stake in shares of Stevanato Group during the 3rd quarter worth $68,000. Finally, Van Berkom & Associates Inc. boosted its stake in shares of Stevanato Group by 50.6% during the 3rd quarter. Van Berkom & Associates Inc. now owns 3,615 shares of the company’s stock worth $93,000 after acquiring an additional 1,215 shares in the last quarter.

About Stevanato Group

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.